Previous 10 | Next 10 |
BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of ...
BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warran...
Unisys (NYSE: UIS ) +39% on being acquired by Science Applications International. More news on: Unisys Corporation, Myomo, Inc., China Xiangtai Food Co., Ltd., Stocks on the move, , Read more ...
Myomo (NYSEMKT: MYO ) +93% on insurance coverage of MyoPro in Germany. More news on: Myomo, Inc., VIVUS, Inc., Camber Energy, Inc., Stocks on the move, , Read more ...
Gainers: Myomo (NYSEMKT: MYO ) +437% . More news on: Myomo, Inc., Allot Ltd., Phibro Animal Health Corporation, Stocks on the move, , Read more ...
Gainers: OpGen (NASDAQ: OPGN ) +49% . More news on: OpGen, Inc., Insmed Incorporated, Artelo Biosciences, Inc., Stocks on the move, , Read more ...
Gainers: Datasea (NASDAQ: DTSS ) +81% . More news on: Datasea Inc., Sintx Technologies, Inc., ReTo Eco-Solutions, Inc., Stocks on the move, , Read more ...
Sintx Technologies (NASDAQ: SINT ) +74% on agreement toward establishing a collaboration framework with Nissin Manufacturing. More news on: Sintx Technologies, Inc., Riot Blockchain, Inc., MYOS RENS Technology Inc., Stocks on the move, , Read more ...
Nano cap miRagen Therapeutics (NASDAQ: MGEN ) jumps 34% premarket on robust volume on the heels of new Phase 1 data on cobomarsen that will be presented at the T-Cell Lymphoma Forum in La Jolla, CA, that starts today. More news on: Miragen Therapeutics, Inc., Healthcare stock...
Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort - - - Median progression free survival (PFS) of 12.5 months compared with 5.4 months in a historical coh...
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...